Progressive supranuclear palsy’s economical burden: the use and costs of healthcare resources in a large health provider in Israel

Abstract

Background Progressive supranuclear palsy (PSP) is a rare and fatal neurodegenerative movement disorder with no disease modifying therapy currently available. Data on the costs associated with PSP are scarce. This study aims to assess the direct medical expenditure of patients with PSP (PwPSP) throughout disease course. Methods This retrospective cohort study is based on the data of a large state-mandated health provider in Israel. We identified PwPSP who were initially diagnosed between 2000 and 2017. Each PwPSP was randomly matched to three health-plan members without PSP by birth-year, sex, and socioeconomic status. Healthcare resources’ utilization and related costs were assessed. Results We identified 88 eligible PwPSP and 264 people in the reference group; mean age at diagnosis was 72.6 years (SD = 8.4) and 53.4% were female. The annual direct costs of PwPSP have risen over time, reaching US$ 21,637 in the fifth year and US$ 36,693 in the tenth year of follow-up vs US$ 8910 in the year prior diagnosis. Compared to people without PSP, PwPSP had substantially higher medical expenditure during the years prior- and post-index date. Conclusion The present study demonstrates higher economic burden, which increases with time, in PwPSP as compared to those without.

New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review

“…Hence, relevant MRI acquisitions were restricted to anatomical sequences such as T1-weighted (T1w) or proton-density-weighted (PDw) imaging (Table 1, SN 1,2,3,6,7,9,10,11,13,14,15,17,18) [87,95,96,99,100,[103][104][105][107][108][109][110][111]. Few studies made use of other techniques beyond those anatomical sequences, including diffusion-weighted imaging (DWI), functional MRI (fMRI), and magnetic resonance spectroscopy (MRS) (Table 1, SN 5,8,12,16,19,20) [42,94,97,98,101,106]. Nearly all studies exclusively used 3-Tesla MRI systems (Table 1, SN 1-21 except 4 and 15) [42,87,[94][95][96][97][98]…”

“…Furthermore, PET techniques varied depending on the study's objectives. Previous work employed PET scanners from different vendors such as General Electrics (GE) Advance PET/computed tomography (CT) (n = 6; Table 1, SN 3,5,6,11,12,17) [42,97,99,100,103,104], GE Discovery PET/CT (n = 6; Table 1, SN 6,11,12,15,17) [42,99,100,102,103,111], and Siemens Biograph HiRez XVI (n = 2), Siemens Biograph mCT (n = 4; Table 1, SN 1,2,18,20) [95,96,101,107], Siemens Biograph mMR (n = 1; Table 1, SN 19) [94], GE SIGNA PET/MRI (n = 2; Table 1, SN 10,16) [87,98], and GE Healthcare PET/CT (n = 5; Table 1, SN 7,8,11,13,14) [105,…”

“…Only six of the included studies reported on the application of additional (advanced) MRI sequences in addition to anatomical imaging with T1w or PDw sequences (Table 1, SN 5,8,12,16,19,20) [42,94,97,98,101,106]. Cope et al used resting-state fMRI in a cohort of AD patients, PSP patients, and HC in conjunction with whole-brain graph-theoretical analysis to systematically investigate global and local network characteristics (such as nodal connectivity strength and other metrics) [97].…”

“…Of note, PSP has a rapid progression rate and substantially affects a patient's quality of life, entailing severe disability and mortality [10,11]. In addition, the considerable rate of misdiagnoses regarding PSP increases the burden on healthcare resources and affects the allocation of appropriate treatment options [12]. While there are no disease-modifying treatments available for PSP to date, management can be offered in the sense of primarily symptomatic and supportive care [1,13].…”

“…SN 1,2,3,4,7,8,9,12,14,15) [42,74,95,96,104,106,[108][109][110][111]]. Furthermore, [11C]PK11195 was used in two previous studies (Table 1, SN 11, 17) [99,100], while [11C]UCB-J was mentioned in Holland et al (Table 1, SN 10) [87] and Mak et al (Table 1, SN 16) [98].…”